Skip to Content
Search Menu

Final analysis of TITAN confirms survival benefit of apalutamide for metastatic castration-sensitive prostate cancer

The final analysis of the TITAN study establishes that adding apalutamide to ADT in patients with metastatic castration-sensitive prostate cancer (mCSPC) leads to significantly improved survival and a consistent side effect profile for the intervention arm

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Related

Neeraj Agarwal

Talazoparib and Enzalutamide: A Game-Changer for mCRPC

/ Neeraj Agarwal
ASCOGU25Prostate cancer Play the Video 18:34

Bone Pain as a Key Prognostic Indicator in Castration-Sensitive Prostate Cancer

/ Deniz Tural / Jan Andreasen
ASCOGU25Prostate cancer
Nick James

Oestrogen Reimagined: A Breakthrough Approach for Metastatic Prostate Cancer

/ Nick James
ASCOGU25Prostate cancer Play the Video 09:06

Norwegian Perspectives on Urogenital Cancer at ESMO 2024

/ BestPractice Nordic
Bladder cancerESMO24Kidney cancerProstate cancer
Gedske Daugaard

Enzalutamide plus Radium223 Treatment as First-Line for mCRPC in a Nordic Perspective

/ Gedske Daugaard
ESMO24Prostate cancer Play the Video 5:55
Silke Gillessen

PEACE-3 study: Enzalutamide and Ra-223 as First-Line Therapy for mCRPC

/ Silke Gillessen
ESMO24Prostate cancer Play the Video 11:05

Androgen Receptor Pathway Inhibitors (ARPIs) Are Superior to Taxanes for Castrate-Resistant Metastatic Prostate Cancer

/ Henrik Grönberg
ESMO24Prostate cancer Play the Video 02:35
Daniel Heinrich

Highlights from ESMO 2024: More Intelligent Choice of Treatment in the Future

/ Daniel Heinrich
Bladder cancerESMO24Kidney cancerProstate cancer Play the Video 4:25
Fred Saad

Darolutamide May Be an Effective Alternative Treatment Option for mHSPC

/ Fred Saad
ESMO24Prostate cancer Play the Video 3:46
Back to top